Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTD1 plus capecitabine versus capecitabine alone in advanced metastatic breast cancer
ChiCTR-TRC-14005100Phase 3Completed
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of utidelone and capecitabine in breast cancer (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.
02
Drugs
utidelonecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-14005100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005100.